The role of immune tolerance in preventing and treating arthritis
Tóm tắt
Từ khóa
Tài liệu tham khảo
Petty RE, Southwood TR, Baum J, et al.: Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997. J Rheumatol 1998, 25:1991–1994.
Sakkas LI, Platsoucas CD: Immunopathogenesis of juvenile rheumatoid arthritis: role of T cells and MHC. Immunol Res 1995, 14:218–236.
Salmon M, Gaston JS: The role of T-lymphocytes in rheumatoid arthritis. Br Med Bull 1995, 51:332–345.
Prinz JC: Disease mimicry—a pathogenetic concept for T cellmediated autoimmune disorders triggered by molecular mimicry? Autoimmun Rev 2004, 3:10–15.
Bonnin D, Prakken B, Samodal R, et al.: Ontogeny of synonymous T cell populations with specificity for a self MHC epitope mimicked by a bacterial homologoue: an antigenspecific T cell analysis in a non-transgenic system. Eur J Immunol 1999, 29:3826–3836.
Medzhitov R, Janeway C, Jr.: The toll receptor family and microbial recognition. Trends Microbiol 2000, 8:452–456.
Kimbrell DA, Beutler B: The evolution and genetics of innate immunity. Nat Rev Genet 2001, 2:256–267.
Aderem A, Ulevitch RJ: Toll-like receptors in the induction of the innate immune response. Nature 2000, 406:782–787.
Albani S, Ravelli A, Massa M, et al.: Immune responses to the Escherichia coli dnaJ heat shock protein in juvenile rheumatoid arthritis and their correlation with disease activity. J Pediatr 1994, 124:561–565.
Abulafia-Lapid R, Elias D, Raz I, et al.: T cell proliferative responses of type 1 Diabetes patients and healthy individuals to human hsp60 and its peptides. J Autoimmunity 1999, 12:121–129.
de Graeff-Meeder ER, Zee R, Rijkers GT, et al.: Recognition of human 60 kD heat shock protein by mononuclear cells from patients with juvenile chronic arthritis. Lancet 1991, 337:1368–1372.
de Kleer IM, Kamphuis SM, Rijkers GT, et al.: The spontaneous remission of juvenile idiopathic arthritis is characterized by CD30+ T cells directed to human heat-shock protein 60 capable of producing the regulatory cytokine interleukin-10. Arthritis Rheum 2003, 48:2001–2010.
Prakken ABJ, Van Eden W, Rijkers GT, et al.: Autoreactivity to human heat-shock protein 60 predicts disease remission in oligoarticular juvenile rheumatoid arthritis. Arthritis Rheum 1996, 39:1826–1832.
Pasare C, Medzhitov R: Toll-like receptors: balancing host resistance with immune tolerance. Curr Opin Immunol 2003, 15:677–682. This paper describes the role of the receptors of the innate immune system on induction of an adaptive immune response. Also suggests a pathogenic role for malfunction of this pathway.
Nolan KF, Strong V, Soler D, et al.: IL-10-conditioned dendritic cells, decommissioned for recruitment of adaptive immunity, elicit innate inflammatory gene products in response to danger signals. J Immunol 2004, 172:2201–2209. This paper shows regulatory effects of an adaptive response on the innate immune system. A very good example of the crosstalk between the two arms of the immune system.
Moreno C, Merino J, Vazquez B, et al.: Anti-inflammatory cytokines induce lipopolysaccharide tolerance in human monocytes without modifying toll-like receptor 4 membrane expression. Scand J Immunol 2004, 59:553–558.
Wolkers MC, Brouwenstijn N, Bakker AH, et al.: Antigen bias in T cell cross-priming. Science 2004, 304:1314–1317.
Tze LE, Baness EA, Hippen KL, Behrens TW: Ig light chain receptor editing in anergic B cells. J Immunol 2000, 165:6796–6802.
Hammerling GJ, Schonrich G, Ferber I, Arnold B: Peripheral tolerance as a multi-stepmechanism. Immunol Rev 1993, 133:93–104.
Ohashi PS, Oehen S, Buerki K, et al.: Ablation of "tolerance" and induction of diabetes by virus infection in viral antigen transgenic mice. Cell 1991, 65:305–317.
Oldstone MB, Nerenberg M, Southern P, et al.: Virus infection triggers insulin-dependent diabetes mellitus in a transgenic model: role of anti-self (virus) immune response. Cell 1991, 65:319–331.
Jonuleit H, Schmitt E, Stassen M, et al.: Identification and functional characterization of human CD4+CD25+ T cells with regulatory properties isolated from peripheral blood. J Exp Med 2001, 193:1285–1294.
Bluestone JA, Abbas AK: Natural versus adaptive regulatory T cells. Nat Rev Immunol 2003, 3:253–257. A major breakthrough in how Treg is thought of. Proposes the coexistance of two major subsets of Treg and discusses their development.
Giannini EH, Brewer EJ, Kuzmina N, et al.: Methotrexate in resistant juvenile rheumatoid arthritis. Results of the USAUSSR double-blind, placebo-controlled trial. N Engl J Med 1992, 326:1043–1049.
Ehrenstein MR, Evans JG, Singh A, et al.: Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J Exp Med 2004, 200:277–285. Interesting report suggesting that anti-TNFα therapy does not only suppress the inflammatory immune response, but also actively modulates the immune response.
Wendling D, Racadot E, Wijdenes J: Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody. J Rheumatol 1993, 20:259–262.
Nishimoto N, Kishimoto T, Yoshizaki K: Anti-interleukin 6 receptor antibody treatment in rheumatic disease. Ann Rheum Dis 2000, 59(Suppl 1):i21-i27.
Nishimoto N, Yoshizaki K, Maeda K, et al.: Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I/II clinical study. J Rheumatol 2003, 30:1426–1435.
Choy EH, Isenberg DA, Garrood T, et al.: Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, doseescalation trial. Arthritis Rheum 2002, 46:3143–3150.
Cutolo M: [IL-1Ra: its role in rheumatoid arthritis]. Reumatismo 2004, 56:41–45.
Silverman GJ, Weisman S: Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy. Arthritis Rheum 2003, 48:1484–1492.
Edwards JC, Szczepanski L, Szechinski J, et al.: Efficacy of Bcell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004, 350:2572–2581.
De Vita S, Zaja F, Sacco S, et al.: Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells. Arthritis Rheum 2002, 46:2029–2033.
Schulze-Koops H, Davis LS, Haverty TP, et al.: Reduction of Th1cell activity in the peripheral circulation of patients with rheumatoid arthritis after treatment with a non-depleting humanized monoclonal antibody to CD4. J Rheumatol 1998, 25:2065–2076.
Chatenoud L: CD3-specific antibody-induced active tolerance: from bench to bedside. Nat Rev Immunol 2003, 3:123–132.
Moreland LW, Alten R, Van den BF, et al.: Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum 2002, 46:1470–1479.
Eagar TN, Karandikar NJ, Bluestone JA, Miller SD: The role of CTLA-4 in induction and maintenance of peripheral T cell tolerance. Eur J Immunol 2002, 32:972–981.
Xiao BG, Link H: Mucosal tolerance: a two-edged sword to prevent and treat autoimmune diseases. Clin Immunol Immunopathol 1997, 85:119–128.
Barnett ML, Combitchi D, Trentham DE: A pilot trial of oral type II collagen in the treatment of juvenile rheumatoid arthritis. Arthritis Rheum 1996, 39:623–628.
Myers LK, Higgins GC, Finkel TH, et al.: Juvenile arthritis and autoimmunity to type II collagen. Arthritis Rheum 2001, 44:1775–1781.
Steenbakkers PG, Baeten D, Rovers E, et al.: Localization of MHC class II/human cartilage glycoprotein-39 complexes in synovia of rheumatoid arthritis patients using complex-specific monoclonal antibodies. J Immunol 2003, 170:5719–5727.
Baeten D, Steenbakkers PG, Rijnders AM, et al.: Detection of major histocompatibility complex/human cartilage gp-39 complexes in rheumatoid arthritis synovitis as a specific and independent histologic marker. Arthritis Rheum 2004, 50:444–451.
Steinman RM, Mellman I: Immunotherapy: bewitched, bothered, and bewildered no more. Science 2004, 305:197–200. This article provides an update on state-of-the-art immunotherapy in basic research and clinic. It also describes difficulties to overcome and where future research should be focused on.
Prakken B, Kuis W, Van Eden W, Albani S: Heat shock proteins in juvenile idiopathic arthritis: keys for understanding remitting arthritis and candidate antigens for immune therapy. Curr Rheumatol Rep 2002, 4:466–473.
Welch WJ, Kang HS, Beckmann RP, Mizzen LA: Response of mammalian cells to metabolic stress; changes in cell physiology and structure/function of stress proteins. Curr Top Microbiol Immunol 1991, 167:31–55.
Jones DB, Coulson AFW, Duff GW: Sequence homologies between hsp60 and autoantigens. Immunol Today 1993, 14:115–118.
Albani S, Keystone EC, Nelson JL, et al.: Positive selection in autoimmunity: abnormal immune responses to a bacterial dnaJ antigenic determinant in patients with early rheumatoid arthritis. Nature Med 1995, 1:448–452.
Windhagen A, Nicholson LB, Weiner HL, et al.: Role of Th1 and Th2 cells in neurologic disorders. Chem Immunol 1996, 63:171–186.
Van Eden W, Thole JER, van der Zee R, et al.: Cloning of the mycobacterial epitope recognized by T lymphocytes in adjuvant arthritis. Nature 1988, 331:171–173.
Van Eden W: Heat-shock proteins as immunogenic bacterial antigens with the potential to induce and regulate autoimmune arthritis. Immunol Rev 1991, 121:5–28.
Albani S, Keystone EC, Nelson JL, et al.: Positive selection in autoimmunity: abnormal immune responses to a bacterial dnaJ antigenic determinant in patients with early rheumatoid arthritis. Nature Med 1995, 1:448–452.
La Cava A, Nelson JL, Ollier WER, et al.: Genetic bias in immune responses to a cassette shared by different microorganisms in patients with rheumatoid arthritis. J Clin Invest 1997, 100:658–663.
Prakken BJ, Samodal R, Le TD, et al.: Epitope-specific immunotherapy induces immune deviation of proinflammatory T cells in rheumatoid arthritis. Proc Natl Acad Sci U S A 2004, 101:4228–4233. Well designed phase I clinical trial that shows the ability of a mucosal route to induce tolerance to a specific antigen systemically. Most likely achieved by the induction of Treg.